Physician profile
Taylor E Hepp
NPI 1669935565
$1,122.96
in general payments reported to CMS, 2019-2025
21 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $168 · 2022: $236 · 2024: $491 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $230.50 | 2021-2022 | |
| Axonics, INC. | $155.06 | 2024 | Axonics |
| Teleflex LLC | $143.52 | 2024 | Urolift |
| Sumitomo Pharma America, INC. | $63.27 | 2024-2025 | Gemtesa, Myfembree |
| Alk-Abello, INC | $54.70 | 2021-2022 | |
| Janssen Biotech, INC. | $53.56 | 2024-2025 | Erleada, Akeega |
| Kaleo, INC. | $52.56 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $40.58 | 2024 | Adstiladrin |
| Procept Biorobotics Corporation | $40.26 | 2025 | |
| Tolmar, INC. | $40.00 | 2024-2025 | Eligard, Jatenzo |
| Progenics Pharmaceuticals, INC. | $33.30 | 2025 | |
| Novartis Pharmaceuticals Corporation | $32.64 | 2025 | |
| Stryker Corporation | $32.04 | 2021 | |
| Pfizer INC. | $24.05 | 2025 | |
| Accord Healthcare, INC. | $22.75 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.65 | 2024 | |
| Alnylam Pharmaceuticals INC. | $19.48 | 2025 | Givlaari |
| Genzyme Corporation | $17.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.42 | 2021 | |
| Novo Nordisk INC | $16.25 | 2024 | Rivfloza |
| Merck Sharp & Dohme LLC | $14.76 | 2024 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Hepp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.